BICX News and Press, BioCorRx Inc. From 05/16/23

2023-05-16 09:01:03 ET BioCorRx press release ( OTCQB:BICX ): Q1 GAAP EPS of -$0.13. For further details see: BioCorRx GAAP EPS of -$0.13

Revenue Increases 97% ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business up...

2023-04-03 14:14:05 ET BioCorRx ( OTCQB:BICX ) FY22 net revenues grew +343% Y/Y to $213.84K due to increased number of patients treated at licensed clinics. "Furthermore, we were pleased to see that membership/program fees also increased for 2022 due to more customers signing up f...

Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics ANAHEIM, CA - ( NewMediaWire ) - April 03, 2023 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse...

BICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma Concentrations BICX104 Subjects Experienced Better 84-Day Treatment Adherence Than Vivitrol® Subjects Company Seeking FDA Approval for Immediate Ex...

ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Dr. Andrew Mallon, CSO and Grant Pri...

Presentation on Thursday, February 2, 2023 at 2:00 PM ET ANAHEIM, CA - ( NewMediaWire ) - January 27, 2023 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, announced today th...

Anaheim, CA - ( NewMediaWire ) - January 19, 2023 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantable...

FREEHOLD, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has appo...

ANAHEIM, CA - ( NewMediaWire ) - December 07, 2022 - BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provide...